The Criteria for the clinical use of immunoglobulin in Australia (the Criteria) undergoes periodic review to reflect the latest scientific evidence and expert advice from our National Immunoglobulin Governance Advisory Committee and its Specialist Working Groups.
This page summarises the changes to the Criteria which were implemented in February 2024. Changes are applied immediately to new authorisations and to existing authorisations at the next continuing treatment request, unless otherwise stated. For more information about any of these changes, please contact the Ig Governance team at IgGovernance@blood.gov.au.
Autoimmune encephalitis mediated by antibodies targeting cell-surface antigens (AMAE) – Version 3.3
- Minor typographical changes.
Guillain–Barré Syndrome (GBS) – Version 3.2
- New text included which reflects the outcomes of a clinical trial demonstrating a second dose of Ig is not beneficial, except where treatment related fluctuations can be demonstrated.
- New qualifying criteria in indication 2 require assessment of disability on three occasions, consistent with the definition of treatment related fluctuations.
- New exclusion criteria have been added to exclude chronic inflammatory demyelinating polyneuropathy from access to Ig treatment under this condition.
- Access to Ig in indication 2 for the specific condition ‘GBS variants’ has been removed.
- Other minor typographical changes.
Heparin induced thrombocytopenia (HIT) – Version 3.0
- New condition added to the Criteria.
Vaccine associated myocarditis and pericarditis (VAMP) – Version 3.0
- New condition added to the Criteria.
Last updated: 03 Feb 2026